Introduction and epidemiology
=============================

Traumatic brain injury (TBI) is commonly defined as any brain pathology caused by an external force. TBI, sometimes referred to as a 'silent epidemic', affects about 69 million people each year, occurs commonly in young adults, and causes a serious burden of devastating health consequences ([@bib1], [@bib2]). The Glasgow Coma Scale (GCS) is used to divide TBI into mild (concussion, 13--15 points), moderate (9--12 points), and severe (3--8 points). Another classification of TBI distinguishes between closed (blunt) and open (penetrating) traumas ([@bib3]); the latter are always severe. It is difficult to determine the actual prevalence and incidence of TBI. Numerous patients with mild injuries neglect further diagnostics or who are treated at primary healthcare centers do not count in hospital statistics. A study based on data from 13 European countries estimated that the incidence of TBI incidence is 235 per 100,000 per year ([@bib4]) and another one reported 506 TBI cases per 100,000 in the USA ([@bib5]). The recent systematic review by Nguyen *et al.* concluded that the pooled annual incidence rate of TBI is 349 per 100,000 person-years. Mild, moderate, and severe TBI pooled annual incidence were 224, 23, and 13 per 100,000, respectively ([@bib6]). In Europe, annual mortality rate associated with TBI was estimated to be 15 per 100,000 ([@bib4]). Head traumas are twice as common in men as in women ([@bib7]). Falls, motor-vehicle and work-related accidents, assaults, as well as sport activities are the most typical causes of brain injuries. Pituitary dysfunction resulting as a consequence of brain injury is not a new phenomenon -- the first article illustrating the matter was published in 1918 ([@bib8]). Nowadays, the topic is gaining more and more attention due to new reports of pituitary insufficiency caused by relatively mild, repetitive brain traumas. The incidence of post-traumatic hypopituitarism (PTHP) is likely underestimated. Based on the review of literature published between May 2000 and October 2018, Benvenga defined that PTHP accounts for 7.2% of the total cases of hypopituitarism ([@bib9]). The prevalence of PTHP among patients with a history of TBI is estimated to be 15--68% ([@bib10], [@bib11], [@bib12]). Symptoms may present at any time after the inflicting trauma ([@bib5]). The severity of brain injuries corresponds to the development of the observed deficiencies: PTHP was diagnosed in 16.8%, 10.9%, and 35.5% of patients with mild, moderate, and severe TBI, respectively ([@bib10], [@bib13]). Insufficiency of somatotropic axis is the most common abnormality, followed by presence of hypogonadism, hypothyroidism, hypocortisolism, and diabetes insipidus ([@bib14], [@bib15], [@bib16]). Pituitary dysfunction after a traumatic brain injury is usually transient and may resolve or regain its functional abilities within 1 to 3 years; however, it can also present itself clinically or develop many years after the initial TBI ([@bib17]).

Pathogenesis
============

The exact mechanism of post-traumatic hypopituitarism remains unclear. Several probable hypotheses have been suggested. The unique location and the intricate vascularization of the pituitary gland plays a key role in the pathogenesis of post-traumatic hypopituitarism ([@bib18], [@bib19]). Shearing forces during brain injuries may damage the vessels supplying the pituitary gland and lead to the necrosis of the pituitary lobes. Similar effect results from compression due to the increased intracranial pressure ([@bib20], [@bib21], [@bib22]). Stalk amputation or stalk displacement caused by mass effect may influence the blood supply to the pituitary lobes ([@bib21]). Moreover, general hypovolemia provides alternative explanations to pituitary gland ischemia. Sheehan syndrome is a well-known consequence of traumatic labor involving significant blood loss ([@bib23]). Additionally, pituitary apoplexy has been reported in a previously healthy adolescent patient after serious thoracic trauma requiring surgery due to the dissection of descending aorta ([@bib24]). Furthermore, thyroidectomy ([@bib25]), CABG ([@bib26]), or lung resection ([@bib27]) has been shown to be probable causes that lead to hypopituitarism in patients with preexisting pituitary enlargement or adenoma.

The impaired vascular supply hypothesis explains the observed hormonal abnormalities seen in post-traumatic hypopituitarism. It correlates well with the distribution of somatotrophs and gonadotrophs which are located in the lateral part of the anterior pituitary lobe and pars tuberalis, respectively -- areas susceptible to ischemia due to portal vessels blood supply ([@bib19]). The central portion of the gland comprising cortico- and thyrotrophs is supplied mainly by short hypophyseal portal vessels and, thanks to that, remains less susceptible to ischemic traumas ([@bib28], [@bib29]). Benvenga *et al.* confirmed MRI changes of the hypothalamus/pituitary area in 93% patients who suffered from post-traumatic pituitary dysfunction ([@bib30]). Fatal TBI cases were associated with pituitary infarction in up to 43% of autopsies ([@bib20]). The hypothalamus is not typically injured in brain trauma; however, increased intracranial pressure may play a role in the apoptosis of cells in the hippocampus, hypothalamus, and the pituitary gland ([@bib31]).

The impact forces generated by traumatic brain injury may directly harm the pituitary gland, especially its stalk, and result in abnormal hormone production ([@bib32], [@bib33], [@bib34]). Head traumas may result in axonal brain injury -- subtle changes to the nerve tissue, detectable only with the use of the newest visualizing techniques ([@bib35]). Experimental studies in animals suggest two additional alternative mechanisms of PTHP. The first one describes inflammation and astrocytosis in hypothalamus-pituitary area ([@bib36]), while the second focuses on tanycytes, the barrier cells of the third ventricle, whose inappropriate junctions may impact the hypothalamus function ([@bib37]).

In recent years, more attention has been put to the link between PTHP and autoimmunity. TBI may induce an inflammation in the nervous system ([@bib38], [@bib39]) as well as an increase in the permeability of blood-brain barrier, resulting in the excessive exposure of pituitary and hypothalamic antigens ([@bib40]). The presence of autoantibodies against pituitary (APA) and hypothalamus (AHA) was reported in patients with post-traumatic hypopituitarism even 5 years after the initial diagnosis ([@bib41]). Tanriverdi *et al.* found APA in 44.8% of patients 3 years after they sustained their brain injury. No antibodies were detected in the control group whose patients were matched by age and gender ([@bib42]). Higher values of APA in post TBI patients were associated with a more frequent development of pituitary insufficiency, while negative antibody titers were associated with a recovery of the pituitary function in a 5-year prospective study ([@bib39], [@bib43]). Antibodies against pituitary gland and hypothalamus (in 22.9% and 21.3% of cases, respectively) were found in a study of 61 professional boxers. Their presence was associated with a higher incidence of hypopituitarism (46.2% vs 10.4%) ([@bib44]). Persistent hypopituitarism in Sheehan's syndrome may have autoimmune background as well, since APA and AHA have been detected in women many years after their initial diagnosis ([@bib45]). Further research is needed to define the exact significance of autoimmune reactions in post-traumatic insufficiency of the pituitary gland. The presence of specific antibodies involved in the development and preservation of pituitary dysfunction can potentially help identify high-risk patients and will allow the development of proper diagnostic and treatment algorithms ([@bib5]).

Interestingly, a reduced risk of PTHP was described in patients with apolipoprotein E3 (APO E3) genotype. APO E3 is a protective protein with confirmed neuronal anti-inflammatory actions ([@bib42]). These findings suggest that complex pathophysiology of PTHP may also have a genetic component. In addition, apolipoprotein E4 was proved to have a neuroprotective effect in patients with a history of concussion ([@bib46], [@bib47]).

Recent research reports that pituitary deficiency after TBI may be also related to an altered miRNA expression profile. Taheri*et al*. found that miR-126-3p and miR-3610 were detected in the serum of patients who developed hypopituitarism on the 1st, 7th, and 28th days and in the 5th year following TBI. Further studies on examining the relationship between various miRNA and pituitary deficiency can help determine the role of specific genes controlled by miRNA. Therefore, miRNA may be used as potential indicators for the early diagnosis of patients who are at a higher risk of developing pituitary deficiency after TBI ([@bib48]).

Sport-induced hypopituitarism
=============================

Sport-induced hypopituitarism (SIHP) is a relatively new endocrine problem. Little is known about the exact incidence of SIHP due to the difficult recognition of the cases. Specifically, contact sports, as well as equestrian and winter sports, and any sports-related fall or injury, are the most common activities that lead to brain injuries. This suggests that mild repetitive brain injuries sustained throughout an athlete's career may accumulate to the magnitude of a severe trauma and lead to pituitary gland dysfunction ([@bib49], [@bib50], [@bib51], [@bib52]). Worldwide, there is a growing popularity of boxing and kickboxing, both of which are known to cause repetitive head trauma and thus pituitary insufficiency ([@bib53]).

In the study of 61 boxers, Tanriverdi found growth hormone deficiency in 15% of them (which correlated with a decreased pituitary volume) and also ACTH deficiency in 8% of the participants ([@bib42]). The same author reported decreased IGF-1 levels in amateur kickboxers; 22% and 9% of them were diagnosed with GH and ACTH deficiency, respectively ([@bib54]). In another study, Kelestimur *et al.* described a negative correlation between stimulated GH peak and both the number of fights and the time spent boxing ([@bib53]).

Football players may be affected by SIHP as well. Hormonal deficiency has been reported in 23.5% of evaluated patients (14.7% presented with growth hormone deficiency, 4.4% presented with hypogonadism, and 4.4% presented with abnormalities in both) ([@bib55]). The literature also describes anecdotal cases of SIHP in swimmers and soccer players ([@bib56], [@bib57]).

Blast-related hypopituitarism
=============================

The relatively high prevalence of chronic hypopituitarism among military veterans attracted more attention to blast injuries as a possible culprit. Wilkinson *et al.* evaluated 26 veterans with a history of blast exposure, among which 11 (42%) presented hormonal abnormalities -- somatotropic and gonadal axes being most affected ([@bib58]). The potential mechanism is likely associated with the blastwave and the secondary injuries that may elicit cell destruction, vascular changes, and diffuse axonal injuries in the pituitary gland ([@bib59], [@bib60]). Growth hormone deficiency was confirmed by the glucagon stimulation test in 25% of 20 soldiers who suffered mild TBI (85% of them as a result of blast injury) ([@bib61]). In another study, Undurti *et al.* compared 39 male soldiers with a history of blast related TBI and 20 soldiers who had not experienced explosion lesions (both groups were deployed under similar conditions). Hormonal abnormalities were detected in 31% and 15% of participants, respectively, with growth hormone deficit being the most common abnormality ([@bib62]). Baxter *et al.* documented a significantly higher ratio (32%) of anterior pituitary dysfunction in patients with a history of direct blast exposure relative to patients with non-blast-TBI (2,6%). The study was extended to include an assessment of the hypothalamic-pituitary area on MRI studies, in which brain scans did not reveal any pathological changes in post-blast patients ([@bib63]).

In addition to the previously mentioned changes, blast related hypopituitarism is also associated with a decreased quality of life, a higher rate of depression, and post-traumatic stress disorders ([@bib61], [@bib62]).

Children and adolescents
========================

Posttraumatic hypopituitarism in children is uncommon. Again, it is difficult to establish its prevalence. Personier *et al.* estimated the incidence of PTHP in children at 8% ([@bib64]). Two studies, one including 198 subjects younger than 2 years of age and a second study with 37 children under 6 years of age did not report any evidence of pituitary dysfunction ([@bib65], [@bib66]). In older children, growth hormone deficiency was present in about 34% of patients 1 year after an injury. Regular auxological assessments are important in the early detection of the condition ([@bib67]) as well as any records of adverse changes in body habitus, as 15% of children with TBI were reported to be overweight during their final evaluation in a study of Jourdan *et al.* ([@bib68]). In a systematic review of literature, Soliman *et al.* estimated that the rates of ACTH, LH/FSH, GH, and TSH deficiencies in children with TBI were 2--43%, 6--16%, 6--48%, and 2--33%, respectively ([@bib69]). Lastly, repetitive TBI in young patients may also have a significant influence on subsequent reproductive complications and physical growth ([@bib70], [@bib71], [@bib72]).

Presentation
============

Traumatic brain injury is a compound disease process beginning at the moment of trauma and evolving with time ([@bib73]). The development of post-traumatic hypopituitarism can vary and may overlap with nonspecific symptoms resulting from the injury. Thus, the diagnosis is often challenging. The delay in the disease recognition and the severity of the hormonal deficits may determine the clinical presentation ([@bib74]). The symptoms resemble other forms of hypopituitarism.

PTHP results in a higher morbidity and mortality ([@bib75]). The survivors face decreased quality of life, adverse changes in their body composition, abnormal metabolic tests, and reduced bone density ([@bib76], [@bib77]). Recent studies attribute more attention to cognitive and affective impairment among the patients, not only due to the brain injury itself but also due to PTHP ([@bib75]). Neuropsychiatric symptoms range from mild to severe and may significantly affect patients' function in the society ([@bib74]). Due to the fact that each anterior pituitary lobe axis is involved, hormone replacement therapy may improve the recovery of cognitive functions ([@bib78], [@bib79], [@bib80]). Thyroid hormones were found to play a role in neurogenesis in rats ([@bib81]). Testosterone substitution may improve memory in patients with hypogonadism ([@bib82]) and protect from an increased risk of Alzheimer's disease ([@bib83]). The influence of estrogen therapy on cognitive function is not fully understood ([@bib84]). Kelly *et al.* confirmed that patients with post-traumatic GH deficiency (GHD) have more severe cognitive impairment than those with normal values of GH ([@bib85]). Several studies reported more frequent deficits in memory and attention, worse reaction-times, as well as emotional problems in subjects with GHD ([@bib86], [@bib87]). In contrary, Pavlovic *et al.* did not detect significant differences between post-traumatic patients with and without GHD ([@bib87]). Lower IGF-1 levels were associated with worse visual memory ([@bib88]) and increased risk of Alzheimer's disease ([@bib89]). Due to the similarity of symptoms, there is a discussion about the contribution of post-TBI hormonal abnormalities to the clinical presentation of PTSD ([@bib62]). Similar psychiatric alterations were found in TBI patients with/without PTHP, but therapy with growth hormone improved mental function ([@bib88], [@bib89], [@bib90]).

Another important abnormality in patients with PTHP is related to changes in metabolic profile. Increased BMI and higher values of total cholesterol as well as its LDL fraction were reported in subjects with PTHP ([@bib75]). Patients with anterior pituitary lobe hormonal deficits post TBI were reported to have increased blood glucose, insulin resistance, dyslipidemia, higher waist circumference, and increased abdominal fat and leptin values ([@bib76], [@bib91]). The probable mechanisms beyond weight gain in patients with PTHP include altered function of hypothalamic nuclei, which control energy homeostasis, changes in circadian rhythms, mood alterations, and bodily response to medications ([@bib73]).

Acute stage
===========

The first 2 weeks following trauma are considered as an acute-phase. Hannon *et al.* defined the prevalence of pituitary dysfunction in 78% of patients with history of traumatic brain injury ([@bib92]). Possible physiological changes, adaptive changes related to their critical condition, or difficulties in performing dynamic testing in these patients make the assessment of hormonal profile challenging. Deficits in gonadotropin and growth hormone are the most common changes among patients in the acute phase of TBI. However, it is absolutely crucial to detect any signs of adrenal insufficiency. No risk factors for ACTH deficits have been identified so far. The condition was found in 78% of hospitalized patients within 10 days of moderate and severe TBI (based on cortisol level lower than 11 µg/dL) ([@bib92]). In another study, Bensalah *et al.* evaluated 200 patients during the first week after they sustained a TBI. He concluded that 2.8%, 21%, and 37% of the patients presented with a cortisol level below 3, 10, and 15 µg/dL, respectively ([@bib93]). Patients with secondary hypocortisolism are known to require a higher level of vasopressors and often suffer from a higher mortality rate ([@bib92], [@bib94]). Since hypoadrenalism is potentially life-threatening, hormone replacement therapy should be introduced immediately. It should be noted that cortisolemia may be affected by drugs (i.e. etomidate, propofol) that were administered in the intensive care units ([@bib94]). Various prolactin levels were reported in patients with PTHP -- hyperprolactinemia may be associated with a reduced inhibiting action of dopamine, often caused by stalk compression and/or physiological reaction to stress ([@bib95]). Other changes such as decreased thyroxin and antidiuretic hormones may also be detected ([@bib96]). These changes are usually transient and resolve within 3--12 months ([@bib97], [@bib98], [@bib99]). Thus, a number of authors cast doubt on the benefits of acute-phase hormonal therapy ([@bib10], [@bib100]). Impaired vasopressin secretion (central diabetes insipidus -- CDI as well as syndrome of inappropriate antidiuretic hormone hypersecretion -- SIADH) in patients with TBI are usually transient, yet sometimes the recovery period may last months ([@bib101]). Central Diabetes Insipidus occurs in 16--28% of patients with TBI ([@bib30], [@bib101]) and correlates with the severity of the trauma, the resulting cerebral edema, and the mortality rate ([@bib82], [@bib102]). Early detection of CDI or SIADH is essential in patients presenting with severed neurological function, where hydro-electrolytic imbalance may be life-threatening ([@bib103]).

Chronic stage
=============

Due to the challenges in evaluating pituitary function during the acute phase post TBI as well as the multitude of dynamic changes that follow the injury, patients should be reassessed in follow-up studies ([@bib5]). The chronic-phase of the PTHP is said to begin 3 months after the initial trauma. Data about the prevalence of the condition are unclear. Between 5.4 to 76.4% of patients present with long-term pituitary hormone abnormalities ([@bib104]). The wide range in presentation is likely due to the significant differences in the diagnostic criteria. It should be underlined that basic hormonal values, without dynamic tests, may lead to inappropriate description of the pituitary function. Similar to the acute phase, growth hormone deficiency and hypogonadism are the two most common anomalies seen in the chronic phase. Long-term ACTH and TSH deficits are relatively rare (less than 10% of cases) ([@bib31]). These results are consistent with the Taniverdi study, where GH, ACTH and LH/FSH deficits were found in 28%, 4%, and 4%, respectively, 5 years post initial trauma ([@bib43]). Central diabetes insipidus is persistent in 7% of patients in long-term observational studies ([@bib101]).

Diagnostic approach
===================

High occurrence of traumatic brain injuries makes routine endocrinological screening controversial. British Neurotrauma Group guidelines recommend performing a hormonal assessment in patients hospitalized for more than 48 h following a TBI ([@bib31]). Patients with a mild TBI should be screened if they present with symptoms of hypopituitarism ([@bib105]). According to the suggested algorithm, first post-acute phase evaluation should be performed between 3 and 6 months after the injury ([@bib31], [@bib100], [@bib106]). Thyroid and gonadal axes assessment includes measurements of TSH, fT4, gonadotropins, estrogens in women, and testosterone in men. Morning cortisol level greater than 18 ug/dL indicates proper ACTH/adrenal function, while a concentration lower than 3 µg/dL is a marker of hypoadrenalism ([@bib31], [@bib107]). Cortisol values between 3 and 18 µg/dL require further investigation through stimulating tests, of which short synacthen test is commonly used ([@bib108]). Somatotropic axis evaluation should be postponed until 1 year after the injury, with the exception of children, who may require earlier assessment. In patients with multi-hormonal abnormalities, low IGF-1 levels may suggest growth hormone deficiency (GHD) ([@bib105]). Various tests can confirm GHD with a high level of confidence ([@bib109], [@bib110]). The possibility of persistent CDI should also be taken into consideration ([@bib106]).

There are valuable algorithms that help predict clinical outcome of severe traumatic brain injury. The IMPACT calculator assesses age, the motor score component of GCS, and the pupillary reaction. The expanded version, including in addition levels of glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and αII-spectrin breakdown products measured in the serum and the cerebrospinal fluid of patients with TBI, correlates with a 6-month mortality rate ([@bib111]). This information may be an invaluable prognostic model; however, it does not refer specifically to the posttraumatic pituitary function. Moreover, the study of the previously mentioned biomarkers is not widely available in clinical practice.

Based on the current available literature and on our own experience, we suggest a novel algorithm for the evaluation of post-traumatic hypopituitarism ([Fig. 1](#fig1){ref-type="fig"}). Figure 1Proposed algorithm for diagnosis of pituitary function after traumatic brain injury (data from Glynn & Agha ([@bib105]), Czeiter *et al.* ([@bib111]), Fernandez-Rodriguez *et al.* ([@bib126]), and Herrmann *et al.* ([@bib127])). TBI, traumatic brain injury; GCS, Glasgow coma scale; TSH, thyroid-stimulating hormone; GH, growth hormone; FSH, follicle stimulating hormone; LH, luteinizing hormone.

Imaging
=======

Radiological presentation of patients with a history of traumatic brain injury varies significantly. Certain changes, especially related to mild TBI, may be undetectable using routine imaging ([@bib35]). Although CT is usually more easily available in acute conditions and provides better visualization of skull fractures, MRI is far superior for assessment of intracranial hematomas, contusion, and shearing injuries, with an estimated sensitivity of 96.4% (compared to a sensitivity of 63.4% for CT studies) ([@bib112], [@bib113]). Kelly *et al.* documented that diffuse brain swelling may be a predictive factor for post-traumatic pituitary dysfunction ([@bib114]). The association between basal skull fractures or diffuse axonal injury and PTHP was identified by Schneider *et al.* ([@bib115]). In addition, patients with PTHP show more chronic abnormalities in magnetic resonance ([@bib16], [@bib116]). Relative to patients who suffered a TBI but did not present with pituitary dysfunction, microstructural damages of the pituitary gland tissues in patients with PTHP present as decreased water diffusion on MRI studies ([@bib117]). Specifically, a reduction in the pituitary size may result from the necrosis and/or intracranial hypertension ([@bib16], [@bib117]). Decreased pituitary volume was also seen in a professional boxer who suffered from GHD when compared to a professional boxer whose GH were within the normal range ([@bib118]). MRI images in further studies may reveal atypical enhancement of the pituitary gland, an empty sella, and/or abnormal pituitary lobe signal ([@bib119]).

Treatment
=========

The cornerstone of treatment of patients with post-traumatic hypopituitarism is hormonal replacement. The general principles of the treatment resemble those used in other forms of pituitary dysfunction ([@bib120]). Deficits in GH, TSH, and LH/FSH are usually transient, and there is no data in the current literature regarding the benefits of hormonal replacement in the acute phase ([@bib10], [@bib101]). In contrast, decreased ACTH/cortisol level should be detected as soon as possible, to ensure appropriate administration of hydrocortisone. Patients who present with ACTH deficiency symptoms should first be stabilized. Next, they should be re-tested, to determine whether they have a persistent hypocortisolism ([@bib121], [@bib122]). Proper hormonal replacement has a potential to reverse the symptoms and to reduce the risk associated with hypocortisolism ([@bib10]). Growth hormone substitution in the chronic phase improves cognitive function, body composition, and quality of life ([@bib91], [@bib123]). In long term studies, even patients without detectable abnormalities in their hormonal profile should be cognizant of possible worrisome signs and symptoms of hypopituitarism ([@bib14]).

Prognosis
=========

A systematic review by Tanriverdi *et al.* concluded that the predictive factors of long-term PTHP include: the presence of intracranial hypertension, the initial severity of brain trauma on the CT scan, the magnitude of diffuse axonal injury, the age of the patient, duration of hospitalization in an intensive care unit, the presence of rapidly changing hormone values, any basal skull fractures, and the presence of anti-pituitary or anti-hypothalamic antibodies ([@bib121]). Persistent GH deficiency is also a negative predictor of one\'s recovery from TBI ([@bib10], [@bib34]). In another study, Hannon *et al.* emphasized the occurrence of acute-phase cortisol deficits as a predictor of mortality and chronic hypopituitarism ([@bib93]). In the majority of cases, PTHP is transient -- probably due to the fact that some pathological changes (i.e. hypoperfusion, intracranial hypertension, and edema) have a reversible character. The possible regeneration of hypophyseal vascularization should be taken into consideration as well ([@bib21]). About 55% of patients with PTHP recover within 3 months, and 74--85% of patients recover within 1 year ([@bib29]). Klose *et al.* reported a similar rate of improvement, documenting 76% of patients affected by early pituitary dysfunction and only 11% 1 year after their TBI ([@bib124]). The recovery of LH/FSH function was seen in most cases, followed by GH and ACTH ([@bib125]). In contrast, Tanriverdi *et al.* reported that 50% of 52 patients were diagnosed with new hormonal abnormalities a year after their TBI. These subjects were re-tested 5 years later and 24% of them presented with chronic hypopituitarism ([@bib98]). However, the prognostic markers and the underlying recovery mechanism from a hypopituitarism state, either immediately after TBI or after a certain period of time, have not yet been determined. As mentioned earlier, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and αII-spectrin breakdown product (SBDP145) are intensively investigated as potential elements of algorithms used for outcome prediction in patients after TBI ([@bib111]).

Further research on the identification of specific antibodies, MiRNAs, neuro anti-inflammatory proteins, and other markers should be carried on, with the ultimate goal of developing indicators for the early diagnosis of patients who may potentially recover or develop pituitary deficiency after sustaining a TBI ([@bib42], [@bib46], [@bib48]).

Conclusions
===========

Traumatic brain injury management is a significant challenge for the healthcare systems in many countries. Lack of proper algorithms leads to the overlooking of post-traumatic hypopituitarism, which may have a great impact on patients' health status and their quality of life. Specific screening methods should be created to identify patients who sustained traumatic brain injuries and who require further observation and/or treatment. Further research is needed to explain the exact mechanisms responsible for pituitary dysfunction resulting from traumatic brain injury. Ultimately, these studies will help healthcare workers prevent PTHP and prepare them to provide optimal treatment to patients with these complications.
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